Welcome to our dedicated page for Fate Therapeutic news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutic stock.
Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company developing induced pluripotent stem cell (iPSC)-derived, off-the-shelf cellular immunotherapies for cancer and autoimmune diseases. This news page aggregates company press releases, clinical updates, financial disclosures, and corporate announcements so readers can follow how Fate Therapeutics’ iPSC-derived CAR T-cell and NK-cell programs progress over time.
Recent news from Fate Therapeutics has highlighted updated Phase 1 clinical data for FT819, its off-the-shelf CD19-targeted CAR T-cell product candidate for systemic lupus erythematosus (SLE), including reports of sustained reductions in disease activity scores, B-cell depletion with immune remodeling, and a favorable safety profile with less-intensive or no conditioning chemotherapy. The company has also issued news on regulatory authorizations to expand FT819 trials into the United Kingdom and European Union, initiation of dose-expansion cohorts in additional autoimmune diseases, and presentations at major medical meetings such as the American College of Rheumatology (ACR) Convergence and the American Society of Hematology (ASH) Annual Meeting.
In oncology, Fate Therapeutics’ news flow includes updates on FT825 / ONO-8250 for advanced HER2-positive solid tumors and FT836, a MICA/B-targeted CAR T-cell program being evaluated without conditioning chemotherapy, as well as preclinical progress on FT839, a dual CAR T-cell candidate co-targeting CD19 and CD38. Investors can also find quarterly financial results, details of corporate restructuring to streamline operations and extend cash runway, and information on executive appointments and employee inducement equity awards.
By reviewing the FATE news feed, readers can track clinical milestones, regulatory interactions, conference presentations, and corporate developments that shape the company’s iPSC-derived cell therapy pipeline. Bookmark this page for a consolidated view of Fate Therapeutics’ latest publicly released information.
Fate Therapeutics, a clinical-stage biopharmaceutical company focusing on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, announced their participation in the 2024 Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2024, at 3:00 PM ET in New York. The event will be webcasted live and accessible on the Company’s website, with an archived version available post-event.
Fate Therapeutics reported its first quarter 2024 financial results and business updates, highlighting progress in clinical areas, including treating the first lupus patient with FT819 CAR T-cell therapy, initiating enrollment for FT522 CAR NK cell therapy, and treating the first patient with FT825 CAR T-cell therapy. The company has $391 million in cash, cash equivalents, and investments. The financial results include $1.9 million in revenue, $53.0 million in operating expenses, and total outstanding shares of 113.8 million.
Fate Therapeutics announced the treatment of the first lupus patient in the Phase 1 autoimmunity study of FT819 CAR T-cell program. The patient showed rapid and potent depletion of CD19+ B cells. The company also presented translational data from the Phase 1 study of FT819 in B-cell malignancies and initial clinical observations from the FT522 CAR NK cell program in B-cell lymphoma. These programs highlight key therapeutic mechanisms for autoimmune diseases.
Fate Therapeutics, Inc. will report its first quarter 2024 financial results and operational updates during a conference call on May 9, 2024. The company focuses on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, with programs like FT819 and FT522. The event coincides with the American Society of Gene and Cell Therapy 27th Annual Meeting.
Fate Therapeutics announced preclinical data for its FT522 program for autoimmune diseases at the ASGCT Annual Meeting. FT522, a CD19-targeted CAR NK cell product candidate, showed promising results in depleting SLE donor B cells and eliminating host immune cells. The ADR technology incorporated into FT522 enhances its potency, potentially offering a new treatment approach for autoimmune diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.